Ignite Creation Date:
2024-05-06 @ 10:49 AM
Last Modification Date:
2024-10-26 @ 12:36 PM
Study NCT ID:
NCT03363178
Status:
UNKNOWN
Last Update Posted:
2017-12-18
First Post:
2017-11-30
Brief Title:
Study to Investigate the Safety and Efficacy of GC3107 BCG Vaccine in Healthy Adults
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Single-arm Open-label Single-center Phase 1 Study to Investigate the Safety and Efficacy of GC3107 BCG Vaccine After Intradermal Administration in Healthy Adults
Status:
UNKNOWN
Status Verified Date:
2017-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Healthy adults will be once administered GC3107BCG Vaccine Intradermally
Detailed Description:
Healthy adults will be once administered GC3107BCG Vaccine Intradermally Tuberculin Skin TestTST will be conducted after 847 days after IP injection and TST result will be read in 4872 hours
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None